Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
This Week's Featured Content The 3 Penny Stocks You Swore You'd Never Buy (But You'll Check Anyway)Reported by Chris Markoch. Published: 1/18/2026. 
Key Points - Vaxart is a clinical-stage biotech developing oral vaccines that could transform global immunization if its platform proves effective.
- Microvision develops cost-effective lidar technology for autonomous vehicles, with upside tied to industry adoption and potential partnerships.
- Datavault AI focuses on monetizing digital data through AI and blockchain tools, offering speculative exposure to the emerging data-as-an-asset theme.
Penny stocks attract speculative investors seeking high-risk, high-reward opportunities. That typically means targeting companies with disruptive technologies, exposure to an emerging trend, or compelling turnaround stories. Many of these firms will never scale, but if one succeeds, investors can see outsized returns. For investors who believe strength lies in numbers, MarketBeat offers a tool that lists the 100 Most Popular Penny Stocks, ranked by the number of MarketBeat subscribers following each company. While follower counts aren't a guarantee of success, they can provide additional conviction in a stock's potential. SpaceX just announced it is rapidly repositioning 4,400 Starlink satellites into lower Earth orbit. While the official explanation points to safety and debris concerns, the move comes days after China labeled Starlink a national security threat, raising serious questions about what's really happening behind the scenes.
If this escalation in space is an early warning signal, most investors won't react until markets already feel the impact. One analyst has updated his playbook for how to protect capital if geopolitical tensions accelerate. See the full briefing and his 3-step plan here Some investors use a $5 cutoff when defining a penny stock. The screener discussed here follows the traditional definition—stocks trading below $1. These securities are highly volatile, so conduct your own research and know your risk tolerance before initiating a position. Vaxart: A Potential Game-Changer for Global Immunization Efforts Vaxart Inc. (NASDAQ: VXRT) is a clinical-stage biotechnology company developing oral vaccines for infectious diseases such as influenza, norovirus and COVID-19. Unlike traditional injectable vaccines, Vaxart's tablet-based platform aims to simplify distribution and improve global accessibility. The bull case for Vaxart centers on its innovative delivery approach. If the company secures FDA approval and scales production, its oral vaccines could reduce logistical barriers to mass immunization and create licensing opportunities. Positive trial results or a commercial collaboration could materially shift sentiment and valuation given the stock's current low base. Clinical risk remains the largest challenge. Vaxart has not yet brought a product to market, and vaccine development is costly and unpredictable. Competition from established players with larger R&D budgets also limits visibility. For now, Vaxart is a long-term speculative bet on platform validation rather than near-term profitability. MarketBeat's analyst ratings show only a single analyst covering Vaxart, which isn't unusual for small biotechs but should raise concerns for investors. VXRT also has only 18% institutional ownership. On the plus side, the stock has about 2% short interest, which may dampen some volatility. Microvision: Developing Cost-Effective LiDAR Units for Autonomous Driving Microvision Inc. (NASDAQ: MVIS) develops LiDAR (light detection and ranging) sensors used in autonomous vehicles, smart infrastructure and industrial sensing. Its hardware and software solutions enable precise 3D mapping needed for self-driving and advanced driver-assistance systems (ADAS). Microvision focuses on compact, cost-effective LiDAR units that could appeal to automakers seeking scalable sensor solutions. The bull case for Microvision depends on two factors: the continued push toward vehicle automation and potential partnerships with major automakers. If the company can demonstrate performance or cost advantages, it could win supply agreements or licensing deals that improve revenue visibility. Microvision's technology may also find uses in robotics and smart-city applications, adding optionality to its growth story. Still, Microvision faces stiff competition from LiDAR players such as Luminar (NASDAQ: LAZR), Innoviz (NASDAQ: INVZ) and Ouster (NYSE: OUST). The timeline for commercial LiDAR adoption has repeatedly slipped, and the path to profitability remains uncertain. MVIS is covered by three analysts and carries a consensus price target of $2.50, implying a 169% gain from its Jan. 15 closing price. Like many speculative names, Microvision has relatively low institutional ownership (around 30%) and high short interest (around 21%). These metrics suggest investors should expect significant volatility. Datavault AI: Trying to Democratize Data Ownership Datavault AI Inc. (NASDAQ: DVLT) operates at the intersection of artificial intelligence, data monetization and digital asset management. The company helps organizations turn raw data into tradable, revenue-generating assets through its patented Datavault platform. By combining AI, blockchain and analytics, Datavault AI aims to democratize data ownership and unlock monetization opportunities that traditional systems overlook. The bullish thesis for Datavault AI rests on its niche focus and scalability potential. As data becomes an increasingly valuable commodity, businesses—and potentially individuals—are seeking ways to safely monetize digital information. Datavault's technology could benefit from broader AI adoption and growing interest in data sovereignty. Early traction or strategic partnerships could catalyze investor confidence. That said, Datavault AI operates in a highly experimental space. Its business model is still evolving, and a clear path to meaningful revenue growth remains unproven. Institutions own less than 1% of the stock, and short interest is over 16% at the time of writing. Investors considering DVLT should view it as a long-term, speculative position betting on the data-as-an-asset thesis rather than near-term earnings potential.
| 
